National Latinx AIDS Awareness Day is turning 20 years and what better moment to reunite all the Directors who have shaped the campaign. They started it, they made it grow, they kept it alive and they transformed it into the national campaign we have today. This conversation provides an opportunity to hear directly from these...
Category: NLAAD Campaign
NLAAD Announces 2023 Webinar Series with Special Focus on Latinos Accessing PrEP
The NLAAD webinar series will kick off TODAY at 3PM ET with a discussion about what is needed to make PrEP into the hands of everyone who needs it. Review the webinar listing below and register now to take part in these important conversations. Webinars are open to everyone. The sessions will include time for...
Registration is Open for NLAAD 2023 Events; including ordering HIV tests and posters
Are you hosting a Testing event? co-organizing a health fair? doing outreach, HIV education? or creating HIV awareness in any way, shape, or form? Then, it’s time to register your 2023 NLAAD event. We would love to celebrate our 20-year anniversary with as many events as possible. To those partners who have joined us in...
Launching of National Latino AIDS Awareness Day 2023: “Do it your Way. Do it Right.”
New York, August 30, 2023— October 15 is National Latinx AIDS Awareness Day (NLAAD). NLAAD promotes HIV Testing, prevention, and treatment within diverse communities to address the health challenges the Hispanic/Latinx community confronts. The 2023 NLAAD’s campaign brings together communities, service providers, and organizations providing services to Hispanics/Latinxs throughout the U.S. and territories under one...
NLAAD celebrates 20 years promoting HIV/AIDS education in the Latino community
First observed in 2003, the National Latino AIDS Awareness Day is celebrating its 20-year anniversary. NLAAD’s first campaign theme was “Open your eyes,” aiming to raise awareness of the HIV/AIDS epidemic in the Hispanic/Latinx community. For 20 years, the team behind NLAAD has worked tirelessly to create awareness year after year in the Latino communities,...
NLAAD: HIV in Hispanics/Latinos During the year 2020
Credits: this summary of the impact of HIV among Hispanics/Latinos by gender, sexual orientation and age group has been prepared by Luis A. Mares, LMSW GENERAL Hispanic/Latino Americans in the United States have to deal with a variety of social determinants of health that put them in a precarious position when it comes to...
Registration of NLAAD events is open, and HIV testing kits request form available for NLAAD 2022 campaign.
Creating awareness in the Hispanic/Latino Community through events nationwide has been the main goal of NLAAD through the years. Now that restrictions due to COVID-19 are not as strict as previous years we hope we can organize live events again. We won’t dismay in our efforts to end the HIV epidemic, and to deliver information and...
Registrations Open for NLAAD Webinar Series 2022
Tuesday October 4th, 3pm “A different PrEP Option: A Presentation for PrEP Professionals” Apretude is the first and only long acting injectable PrEP for reducing the risk of getting HIV. Join us to this presentation given by ViiV laboratories with information about this new important medical advance in the HIV field. [Registration link] Wednesday...
Launching of National Latino AIDS Awareness Day 2022: “You Choose!”
New York, September 15, 2022- October 15th is National Latinx AIDS Awareness Day (NLAAD). NLAAD’s campaign brings together Hispanic/Latinx communities and service providers, and organizations providing services to Hispanic/Latinx throughout the U.S. and territories under one theme. This year’s theme “You Choose!” informs us about new developments in the scientific field of HIV, that provide us...
U.S. FDA Approves CABENUVA for Use Every Two Months, Expanding the Label of the First and Only Long-Acting HIV Treatment
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed adults (HIV-1 RNA less than 50 copies per...